Cite
Engineered HCMV‐infected APCs enable the identification of new immunodominant HLA‐restricted epitopes of anti‐HCMV T‐cell immunity.
MLA
Santamorena, Maria Michela, et al. “Engineered HCMV‐infected APCs Enable the Identification of New Immunodominant HLA‐restricted Epitopes of Anti‐HCMV T‐cell Immunity.” HLA: Immune Response Genetics, vol. 103, no. 6, June 2024, pp. 1–27. EBSCOhost, https://doi.org/10.1111/tan.15541.
APA
Santamorena, M. M., Tischer, Z. S., Bonifacius, A., Mireisz, C. N., Costa, B., Khan, F., Kulkarni, U., Lauruschkat, C. D., Sampaio, K. L., Stripecke, R., Blasczyk, R., Maecker, K. B., Kraus, S., Schlosser, A., Cicin, S. L., Kalinke, U., & Eiz, V. B. (2024). Engineered HCMV‐infected APCs enable the identification of new immunodominant HLA‐restricted epitopes of anti‐HCMV T‐cell immunity. HLA: Immune Response Genetics, 103(6), 1–27. https://doi.org/10.1111/tan.15541
Chicago
Santamorena, Maria Michela, Zimmermann, Sabine Tischer, Agnes Bonifacius, Chiara Noemi‐Marie Mireisz, Bibiana Costa, Fawad Khan, Upasana Kulkarni, et al. 2024. “Engineered HCMV‐infected APCs Enable the Identification of New Immunodominant HLA‐restricted Epitopes of Anti‐HCMV T‐cell Immunity.” HLA: Immune Response Genetics 103 (6): 1–27. doi:10.1111/tan.15541.